← All trials
NCT05507983
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Dec 1, 2023
- Completion date
- Jan 1, 2024
- First posted
- Aug 19, 2022
- Last posted
- Aug 19, 2022
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maastricht UniversityLead sponsor
- Red Cross Hospital BeverwijkCollaborator
- University of GroningenCollaborator
- Association of Dutch Burn CentresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.